Ultragenyx Pharmaceutical traded at $51.57 this Friday August 12th, increasing $0.32 or 0.62 percent since the previous trading session. Looking back, over the last four weeks, Ultragenyx Pharmaceutical gained 21.66 percent. Over the last 12 months, its price fell by 44.39 percent. Looking ahead, we forecast Ultragenyx Pharmaceutical to be priced at 54.06 by the end of this quarter and at 49.69 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
51.57
Daily Change
0.62%
Yearly
-44.39%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Kyowa Hakko Kirin 3,185.00 65.00 2.08% -7.95%
Acadia Pharmaceuticals 16.40 0.66 4.19% -6.71%
Agios Pharmaceuticals 28.15 2.16 8.31% -35.95%
Alnylam Pharmaceuticals 233.85 4.46 1.94% 18.98%
Aptinyx Inc 0.41 -0.19 -32.33% -83.15%
BioCryst Pharmaceuticals 14.64 0.27 1.88% -9.35%
Bluebird Bio 6.72 0.41 6.50% -63.62%
BioMarin Pharmaceutical 95.07 0 0% 26.71%
Epizyme 1.47 -0.02 -1.34% -72.88%
Esperion Therapeutics 6.70 0.06 0.90% -51.83%
Insmed 27.26 0.51 1.91% 15.70%
Ionis Pharmaceuticals 44.10 0.66 1.52% 11.14%
Karyopharm Therapeutics 5.41 0.45 9.07% 10.86%
MacroGenics 5.22 0.13 2.55% -77.49%
Moderna Inc 171.18 -0.63 -0.37% -56.08%
Mirati Therapeutics 86.37 5.92 7.36% -38.38%
Neurocrine Biosciences 105.63 0.75 0.72% 18.53%
Puma Biotechnology 3.51 -0.04 -1.13% -51.65%
PTC Therapeutics 52.75 0.74 1.42% 31.84%
Ultragenyx Pharmaceutical 51.57 0.32 0.62% -44.39%
Regeneron Pharmaceuticals 628.71 4.81 0.77% 0.63%
Sarepta Therapeutics 109.00 -0.26 -0.24% 36.35%
Vertex Pharmaceuticals 294.52 2.36 0.81% 51.53%
Immunic Inc. 5.25 0.33 6.71% -44.50%
Xoma 20.08 -0.45 -2.19% -31.98%

Indexes Price Day Year
USND 13047 267.27 2.09% -11.98%
US2000 2017 41.36 2.09% -9.29%

Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company's therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy and nucleic acid product candidates. Its three approved product candidates include Crysvita (burosumab), for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa), for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome and Dojolvi (triheptanoin), for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD). Its clinical product candidates include DTX401, for the treatment of glycogen storage disease type Ia (GSDIa), DTX301, for the treatment of ornithine transcarbamylase (OTC), UX143, GTX-102, UX701 and UX053.